TABLE 2.
Protection by treatment in vitro with TRL345 of MRC-5 fibroblasts from infection by clinical isolates of diverse genotypes
| Isolate | gB serotype group | FFU with no antibodya | FFU with TRL345 |
|---|---|---|---|
| CSL001 | 1 | 6 | 0 |
| 32524 | 1 | 4 | 0 |
| 32692 | 1 | 4 | 0 |
| 32583 | 2 | 4 | 0 |
| 32691 | 2 | 2 | 0 |
| 32195 | 2 | 2 | 0 |
| 32613 | 3 | 5 | 0 |
| 32635 | 3 | 4 | 0 |
| CLS006 | 3 | 3 | 0 |
| 32516 | 3 | 3 | 0 |
| 32493 | 3 | 2 | 0 |
| 32514 | 3 | 2 | 0 |
| UXCM | NDb | 5 | 0 |
| 32648 | ND | 2 | 0 |
| 32552 | ND | 1 | 0 |
Focus-forming units (FFU) were counted at 10 to 12 days postinfection.
ND, not determined.